VESALIUS-CV – assessing the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
ORION 4 – examining the effects of inclisiran, a small interfering RNA (siRNA) that inhibits the synthesis of PCSK9, on cardiovascular outcomes among individuals with atherosclerotic cardiovascular disease.
REAL – evaluating the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult subjects presenting with acute STEMI (ST segment elevation myocardial infarction).
DAPA ACT HF – an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (LVEF ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcome of cardiovascular death or worsening heart failure.
COVID-PACT – a multicenter, randomized, open-label, 2 x 2 factorial design trial of full-dose anticoagulation vs. standard-dose prophylactic anticoagulation and antiplatelet therapy vs. no antiplatelet therapy on the risk of venous or arterial thrombotic events in ICU patients with COVID-19.
TIMI 67 – a study to evaluate efficacy, safety and tolerability of AMG 890 (a small interfering RNA) in subjects with elevated lipoprotein(a).
TRANSLATE – a phase 2b trial testing multiple doses of vupanorsen, an antisense oligonucleotide (ASO) against angiopoietin-like 3 (ANGPTL3) protein, for safety and efficacy in non-HDL-C lowering.